Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688796's EV-to-FCF is ranked worse than 92.26% of 336
companies
in the Biotechnology industry
Industry Median: 15.16
vs SHSE:688796: 155.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio (TTM) for today is calculated as:
Biocytogen Pharmaceuticals (Beijing) Co's share price for today is ¥120.78.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.430.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-FCF Related Terms
Biocytogen Pharmaceuticals (Beijing) Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-FCF Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
SHSE:688796 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-FCF vs Biotechnology Industry
Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is ¥43,991 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was ¥282 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) has a EV-to-FCF of 155.76 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #310 out of 336 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF too high?
Biocytogen Pharmaceuticals (Beijing) Co's current EV-to-FCF is 155.76. The Biotechnology industry median EV-to-FCF is 15.16. Biocytogen Pharmaceuticals (Beijing) Co's value of 155.76 is 927.4% above this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #310 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #310 out of 336 companies for EV-to-FCF. This places Biocytogen Pharmaceuticals (Beijing) Co in the lower half of its industry. The industry median EV-to-FCF is 15.16. Biocytogen Pharmaceuticals (Beijing) Co's value of 155.76 is 927.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.16, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current EV-to-FCF of 155.76 is 927.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current EV-to-FCF is 155.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥45.10, compared to a current price of ¥120.78 — trading 167.8% above its estimated fair value. The current EV-to-FCF is 155.76 and 927.4% above the Biotechnology industry median of 15.16. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796), the current EV-to-FCF is 155.76 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (SHSE:688796) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of ¥120.78 is trading 167.8% above its estimated GF Value™ of ¥45.10.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for SHSE:688796:
EV-to-FCF: 155.76
GF Value™: ¥45.10 vs. price of ¥120.78 (167.8% above fair value)
Industry Position: 927.4% above the Biotechnology median (#310 of 336)
No single metric tells the full story. See the SHSE:688796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
45GF Score
Get the complete analysis for SHSE:688796
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688796 has been successfully added to your 
